Experience

Humanity Talent Network
• Health and Human Services
• 1 - 100 Employee
• Advisory Board Member

  • Sep 2022 - Present


Julz Pharma

• Biotechnology

• Chief Medical Officer

  • Jan 2019 - Present

  • A cross fertilized pharma incubator vehicle to bring innovative therapeutics for China bridging US Expertise. A biotech investment hedge fund Platform Developing the clinical, business development and medical affairs foundational platform and tactical execution support structure for an in-development incubator pharma https://www.julzpharma.com/ • Focused primarily on Asia Pacific and China markets with portfolio acquisition in process spanning oncology, cardiometabolic, inflammation &… Show more • A cross fertilized pharma incubator vehicle to bring innovative therapeutics for China bridging US Expertise. A biotech investment hedge fund Platform Developing the clinical, business development and medical affairs foundational platform and tactical execution support structure for an in-development incubator pharma https://www.julzpharma.com/ • Focused primarily on Asia Pacific and China markets with portfolio acquisition in process spanning oncology, cardiometabolic, inflammation & autoimmune diseases, rare disorders Structure, Deal flow and Series A financing currently partially suspended due to COVID-19 Show less • A cross fertilized pharma incubator vehicle to bring innovative therapeutics for China bridging US Expertise. A biotech investment hedge fund Platform Developing the clinical, business development and medical affairs foundational platform and tactical execution support structure for an in-development incubator pharma https://www.julzpharma.com/ • Focused primarily on Asia Pacific and China markets with portfolio acquisition in process spanning oncology, cardiometabolic, inflammation &… Show more • A cross fertilized pharma incubator vehicle to bring innovative therapeutics for China bridging US Expertise. A biotech investment hedge fund Platform Developing the clinical, business development and medical affairs foundational platform and tactical execution support structure for an in-development incubator pharma https://www.julzpharma.com/ • Focused primarily on Asia Pacific and China markets with portfolio acquisition in process spanning oncology, cardiometabolic, inflammation & autoimmune diseases, rare disorders Structure, Deal flow and Series A financing currently partially suspended due to COVID-19 Show less



Consulting

• IT Services and IT Consulting

• Executive Medical Affairs & Clinical Development Consultant

  • Jan 2019 - Present

  Through Boutique Network and Expertise Driven Partnerships: Providing end -to-end strategic & tactical services as well as functional capability enhancement to small cap CMOs and life science leadership in areas of Value based Clinical Development, Pharmacovigilance, TPP Risk Mitigations, Integrated Medical Affairs Strategy, Medical Launch Planning & Competetive Positioning, Early Product planning & Trial Design Optimizations, Value & Evidence generation, BIG DATA & real-world evidence, Health… Show more Through Boutique Network and Expertise Driven Partnerships: Providing end -to-end strategic & tactical services as well as functional capability enhancement to small cap CMOs and life science leadership in areas of Value based Clinical Development, Pharmacovigilance, TPP Risk Mitigations, Integrated Medical Affairs Strategy, Medical Launch Planning & Competetive Positioning, Early Product planning & Trial Design Optimizations, Value & Evidence generation, BIG DATA & real-world evidence, Health Economics, Multichannel Medical Engagement, Due Diligences • Key Therapeutic Area Focus: o Oncology/Hematology (SCLC, NSCLC, TNBC, HCC, RCC, Myeloproliferative Disorders, Radionucleotides, Glioblastoma) – Myelopreservation, Kinase Inhibitors, FAP, CDK4/6 inhibitor, Cell based Immune Therapies, IL-2, IL-4, IL-13 superkines, IntraTumoral Immune Primers, PD-L1, , CIK-CAR Immunotherapy o Gene Therapies, Rare Diseases, Rheumatology, Neurodegeneration, Digital Therapeutics Show less Through Boutique Network and Expertise Driven Partnerships: Providing end -to-end strategic & tactical services as well as functional capability enhancement to small cap CMOs and life science leadership in areas of Value based Clinical Development, Pharmacovigilance, TPP Risk Mitigations, Integrated Medical Affairs Strategy, Medical Launch Planning & Competetive Positioning, Early Product planning & Trial Design Optimizations, Value & Evidence generation, BIG DATA & real-world evidence, Health… Show more Through Boutique Network and Expertise Driven Partnerships: Providing end -to-end strategic & tactical services as well as functional capability enhancement to small cap CMOs and life science leadership in areas of Value based Clinical Development, Pharmacovigilance, TPP Risk Mitigations, Integrated Medical Affairs Strategy, Medical Launch Planning & Competetive Positioning, Early Product planning & Trial Design Optimizations, Value & Evidence generation, BIG DATA & real-world evidence, Health Economics, Multichannel Medical Engagement, Due Diligences • Key Therapeutic Area Focus: o Oncology/Hematology (SCLC, NSCLC, TNBC, HCC, RCC, Myeloproliferative Disorders, Radionucleotides, Glioblastoma) – Myelopreservation, Kinase Inhibitors, FAP, CDK4/6 inhibitor, Cell based Immune Therapies, IL-2, IL-4, IL-13 superkines, IntraTumoral Immune Primers, PD-L1, , CIK-CAR Immunotherapy o Gene Therapies, Rare Diseases, Rheumatology, Neurodegeneration, Digital Therapeutics Show less


Acer Therapeutics Inc.
• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee
• Vice President, Medical Affairs

  • Jul 2018 - Dec 2018

Trevena, Inc.
• United States
• Biotechnology Research
• 1 - 100 Employee
• Senior Director, Medical Affairs & HEOR

  • Oct 2016 - Jul 2018

AstraZeneca
• United Kingdom
• Pharmaceutical Manufacturing
• 700 & Above Employee
• Sr. Medical Affairs Leader- Neuroscience, Global Medical Affairs

  • Feb 2014 - Sep 2016


sanofi-aventis

• France
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Sr. Director, Head of Oncology-Global Evidence & Value Development, Medical Affairs + Global R&D

  • Apr 2012 - Jan 2014

• Director, Oncology Global Evidence & Value Development (EVD)-Medical Affairs

  • Feb 2011 - Apr 2012


Amgen
• United States
• Biotechnology Research
• 700 & Above Employee
• Sr Manager Global Health Economics- Bone Health

  • Aug 2008 - Feb 2011